Prometheus Laboratories Inc. Risk Report

📜 Innovation & R&D

Prometheus Laboratories Inc. has demonstrated notable strides in the field of precision medicine and diagnostics, focusing primarily on biotechnology research and applications for inflammatory bowel disease (IBD). The company's efforts in clinical laboratory diagnostics and gastrology have advanced with their cutting-edge tests and partnerships. Noteworthy projects and studies underscore their commitment to innovation, further expanding their impact in biotechnological advancements.

• Prometheus Laboratories launched their first pre-therapy test to gauge the likelihood of biological response 🗓 April 29, 2025, demonstrating their ongoing dedication to precision healthcare.
• On 🗓 June 17, 2025, their PredictrPK(R) ADA test showed strong clinical utility, supporting treatment optimization for adalimumab.
• The firm partnered with Takeda to develop CDPATH™, a personalized tool for Crohn's disease patients, announced 🗓 September 14, 2022.
• On 🗓 March 12, 2021, Prometheus Biosciences raised $190 million during its IPO aimed at R&D for inflammatory bowel disease.
• Prometheus launched a new indication for their PredictrPK(R) IFX dosing test for IBD patients 🗓 March 2, 2023.